<DOC>
	<DOCNO>NCT02600780</DOCNO>
	<brief_summary>Febuxostat potent , nonpurine , selective inhibitor Xanthine oxidase exhibit antihyperuricemic activity reduce formation uric acid . The investigator conduct interventional , two-arm , randomize , open label pilot study patient serum urate level ≥ 6.8 mg/dL . Patients treat Febuxostat 40 mg Tablets Allopurinol 300 mg Tablets daily dose 90 day determine efficacy safety Febuxostat comparison Allopurinol Hyperuricemic Subjects without Gout .</brief_summary>
	<brief_title>Zurig ( Febuxostat ) 40mg Efficacy Safety Trial</brief_title>
	<detailed_description>Patients hyperuricemia ( without Gout ) randomize two group . One treat Febuxostat 40 mg Tablets Allopurinol 300 mg Tablets daily 3 month period . Gender , age , height , weight , creatinine ALT level , co-morbidities complication monitor screen per eligibility criterion 50 patient enrol study . Efficacy determine monitor serum uric acid level end treatment . The safety profile also monitor treatment period . Investigator collect record data visit CRF analyze SPSS version 20 .</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Both gender 18 75 year age 2 . Must serum urate level ≥ 6.8 milligram per deciliter ( mg/dL ) and/or subject recruit Gout ; must meet American College Rheumatology criterion Gout . 3 . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . 4 . Patient willingly provide write informed consent 1 . History significant concomitant illness 2 . Active liver disease ( SGPT &gt; 1.5 time upper limit normal range ) 3 . Severe renal impairment ( Serum Creatinine level &gt; 2mg/dl ) 4 . Any significant medical condition would interfere treatment , safety compliance protocol , define investigator 5 . Cardiac disease stroke ( current previous history ) 6 . Has know history infection hepatitis B , hepatitis C , HIV 7 . Has history cancer within 5 year prior first dose study medication 8 . Has know hypersensitivity febuxostat allopurinol component formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Febuxostat</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Hyperuricemia</keyword>
	<keyword>Zurig</keyword>
	<keyword>Getz Pharma</keyword>
</DOC>